Sun Pharma Advanced Research Co (NSE:SPARC) Cash-to-Debt : 3.27 (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Sun Pharma Advanced Research Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Sun Pharma Advanced Research Co's cash to debt ratio for the quarter that ended in Mar. 2024 was 3.27.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Sun Pharma Advanced Research Co could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Sun Pharma Advanced Research Co's Cash-to-Debt or its related term are showing as below:

NSE:SPARC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07 Med: 2.9 Max: 128.95
Current: 3.27

During the past 13 years, Sun Pharma Advanced Research Co's highest Cash to Debt Ratio was 128.95. The lowest was 0.07. And the median was 2.90.

NSE:SPARC's Cash-to-Debt is ranked better than
66.6% of 1051 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs NSE:SPARC: 3.27

Sun Pharma Advanced Research Co Cash-to-Debt Historical Data

The historical data trend for Sun Pharma Advanced Research Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Sun Pharma Advanced Research Co Cash-to-Debt Chart

Sun Pharma Advanced Research Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash-to-Debt

Get a 7-Day Free Trial

0.13

0.07

0.16

25.68

3.27

Sun Pharma Advanced Research Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															25.68	N/A	26.64	N/A	3.27

Competitive Comparison of Sun Pharma Advanced Research Co's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sun Pharma Advanced Research Co's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Sun Pharma Advanced Research Co's Cash-to-Debt falls into.

Sun Pharma Advanced Research Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Sun Pharma Advanced Research Co's Cash to Debt Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1999.2	/	(504.9	+	106.6)
	=	3.27

Sun Pharma Advanced Research Co's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1999.2	/	(504.9	+	106.6)
	=	3.27

Sun Pharma Advanced Research Co (NSE:SPARC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Sun Pharma Advanced Research Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Sun Pharma Advanced Research Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Sun Pharma Advanced Research Co (NSE:SPARC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sun Pharma Advanced Research Co Ltd (NSE:SPARC) » Definitions » Cash-to-Debt

Traded in Other Exchanges

532872:India

Address

Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093

Website

https://www.sparc.life

Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Sun Pharma Advanced Research Co (NSE:SPARC) Headlines

No Headlines